iRGD-guided tamoxifen polymersomes inhibit estrogen receptor transcriptional activity and decrease the number of breast cancer cells with self-renewing capacity

BACKGROUND: Tamoxifen (Tam) is the most frequent treatment for estrogen receptor (ER) positive breast cancer. We recently showed that fibronectin (FN) leads to Tam resistance and selection of breast cancer stem cells. With the aim of developing a nanoformulation that would simultaneously tackle ER a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Nanobiotechnology
Päätekijät: Diaz Bessone, María Inés, Simón-Gracia, Lorena, Scodeller, Pablo, Ramirez, María de los Angeles, Lago Huvelle, María Amparo, Soler-Illia, Galo J. A. A., Simian, Marina
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6898937/
https://ncbi.nlm.nih.gov/pubmed/31812165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12951-019-0553-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia